drugset
drugset / Trial / NCT02298387

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

NCT02298387 ↗

Phase 1 Completed 71 enrolled OncoMed Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Timeline

Start
2014-12-22
Primary completion
2017-05-23
Completion
2017-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject navicixizumab Monoclonal antibody 0.5 mg/kg Intravenous
Subject navicixizumab Monoclonal antibody 1 mg/kg Intravenous
Subject navicixizumab Monoclonal antibody 2.5 mg/kg Intravenous
Subject navicixizumab Monoclonal antibody 5 mg/kg Intravenous
Subject navicixizumab Monoclonal antibody 10 mg/kg Intravenous

Indications

high grade malignant neoplasm